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Abstract The social and economic burdens of dialysis
are growing worldwide as the number of patients increases.
Dialysis is becoming a heavy burden even in developed
countries. Thus, preventing end-stage kidney disease is of
the utmost importance. Early detection and treatment is
recommended because late referral is common, with most
chronic kidney disease (CKD) patients remaining asymp-
tomatic until a late stage. Three-quarters of dialysis
patients initiated dialysis therapy within 1 year after
referral to the facility. Since its introduction in 2002, the
definition of CKD has been widely accepted not only by
nephrologists but also by other medical specialties, such as
cardiologists and general practitioners. Japan has a long
history of general screening for school children, university
students, and employees of companies and government
offices, with everybody asked to participate. The urine test
for proteinuria and hematuria is popular among Japanese
people; however, the outcomes have not been well studied.
We examined the effects of clinical and laboratory data
from several sources on survival of dialysis patients and
also predictors of developing dialysis from community-
based screening (Okinawa Dialysis Study, OKIDS). At an
early CKD stage, patients are usually asymptomatic;
therefore, regular health checks using a urine dipstick and
serum creatinine are recommended. The intervals for
follow-up, however, are debatable due to the cost. CKD is a
strong risk factor for developing cardiovascular disease
and death and also plays an important role in infection and
malignancies, particularly in elderly people. People can
live longer with healthy kidneys.
Keywords Survival  Predictor  Chronic kidney disease
(CKD)  End-stage kidney disease (ESKD)  Proteinuria
Introduction
Although kidney disease patients can survive without
kidney function, dialysis is a life-saving procedure. How-
ever, many complications related to chronic kidney disease
(CKD) have not been resolved, including cardiovascular
disease (CVD), mineral and bone disorders (CKD-MBD),
and infection [1]. Nephrology is a relatively new sub-spe-
cialty in the field of internal medicine, and we are still
learning the extent of how the kidneys support the body.
The social and economic burdens of dialysis are growing
worldwide as the number of patients increases. Dialysis is
becoming a heavy burden even in developed countries.
Thus, preventing end-stage kidney disease (ESKD) is of
the utmost importance. Early detection and treatment is
recommended because late referral is common, with most
CKD patients remaining asymptomatic until a late stage.
According to the annual report from the Japanese Society
for Dialysis Therapy (JSDT), three-quarters of dialysis
patients initiated dialysis therapy within 1 year after
referral to the facility [2].
CKD is clinically defined by the presence of albuminuria
and/or a decrease in kidney function for[3 months. Since its
introduction in 2002, the definition of CKD has been widely
accepted not only by nephrologists but also other medical
specialties, such as cardiologists and general practitioners.
Japan has a long history of universal screening for school
children, university students, and employees of companies
and government offices. The urine test for proteinuria and
hematuria is popular among Japanese people; however, the
outcomes have not been well studied.
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Okinawa dialysis study (OKIDS)
Chronic dialysis therapy was started in Okinawa in 1971,
several years after it was initiated in other parts of Japan
[3–5]. The number of dialysis patients per million popu-
lation (pmp) is increasing faster in Okinawa than the
national average (Fig. 1). The number was 1,982 in 1990
and 5,246 in 2000 when the population was 1.2 million
(1990) and 1.3 million (2000), respectively. The number of
dialysis units was 27 in 1990 and 56 in 2000. Initially, the
objective of the OKIDS was to determine the relative risk
of CVD, including stroke and acute myocardial infarction,
in dialysis patients. The strengths of the study are that all of
the medical facilities have cooperated, and the data for the
incidence of CVD in the general population were available
at the same time in Okinawa. We found that the relative
risk of stroke, in particular cerebral hemorrhage was very
high, but not as high as acute myocardial infarction. The
incidence of cerebral hemorrhage was higher than in the
general population, even for normotensive dialysis patients
[6, 7].
We examined the effects of clinical and laboratory data
from several sources on survival [8–18]. Among them,
serum albumin was a strong predictor of death, suggesting
the importance of nutritional management [9]. Heart failure
has been the leading cause of death among dialysis patients.
Our data suggest that factors other than atherosclerotic heart
disease lead to heart failure in the dialysis population. The
overall survival was higher for those with a higher blood
pressure and total serum cholesterol, which contradicts data
from the general population. These observations were later
recognized as ‘reverse epidemiology’ [19]. Dialysis patients
have multiple modifiable risk factors. Table 1 summarizes
the factors related to poor survival in chronic dialysis
patients [20].
Several randomized controlled trials, such as the treat-
ment of anemia using an erythropoietin-stimulating agent
[21, 22] and statin treatment [23, 24], have failed to show
an improvement in survival. Hypertension is a major risk
factor for death and cardiovascular disease in dialysis
patients, but the effect of lowering blood pressure in this
high-risk patient group is uncertain. We examined the
effect of an angiotensin receptor blocker on survival [25].
In a multicenter prospective, randomized, open-label,
blinded-endpoint trial, we assigned 469 patients on chronic
hemodialysis (HD) with hypertension to receive the
angiotensin receptor blocker olmesartan (n = 235) or a
treatment other than an angiotensin receptor blocker or
angiotensin-converting enzyme inhibitor (n = 234).
Lowering blood pressure with an angiotensin receptor
blocker did not significantly lower the risk of major
cardiovascular events or death among patients with
hypertension on chronic HD [26].
Two community-based registries for ESKD patients and
general screening have been available to us [27, 28]. The
Okinawa General Health Maintenance Association
(OGHMA) has been performing universal screening
annually in Okinawa. Since 1983, they have filed records in
the computer registry. With full collaboration of the
physicians and medical staff, we were able to match sub-
jects who participated in the screening and later developed
ESKD. Because the area consists of sub-tropical islands,
the ESKD or CKD stage 5 patients reside exclusively
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Fig. 1 Prevalence of chronic
dialysis patients per million
population in Okinawa and
Japan (cited from ref. [2])
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(n = 106,182) and 1993 (n = 143,948), we analyzed the
relationship between commonly measured laboratory
variables and ESKD [27–40]. The total number of identi-
fied ESKD patients was 420 from 1983 to 2000.
Among the variables examined, dipstick proteinuria had
the strongest association; the greater the dipstick protein-
uria, the higher the risk of developing ESKD (Fig. 2) [28].
Although the dipstick test is ‘semi-quantitative’, the test is
clearly ‘dose-dependent’. Serum creatinine was tested in
14 % of patients in 1983 and 35 % in 1993. In addition to
dipstick proteinuria, hematuria, blood pressure, body mass
index (BMI), serum creatinine, uric acid, and anemia were
significant predictors of developing ESKD. Other factors,
such as smoking, plasma glucose, dyslipidemia, and met-
abolic syndrome, also played a role in the development of
CKD and ESKD, suggesting the necessity of a multidis-
ciplinary approach. The risk factors related to the devel-
opment of ESKD are summarized in Table 2 [41].
Only a few studies outside Japan have examined the
effect of microhematuria on developing ESKD. Microhe-
maturia is relatively common, particular in elderly women.
Compared to proteinuria, the risk of microhematuria was
significant, but showed a weak dose–response relationship.
The absolute risk of microhematuria was low but was a
statistically significant predictor of ESKD [42]. Notably,
microhematuria is a risk factor for developing proteinuria;
if combined with proteinuria, the risk of developing ESKD
is even higher compared to having proteinuria alone [43].
The Japanese Society for Dialysis Therapy (JSDT)
The JSDT has been conducting a nationwide survey on
chronic dialysis therapy and reporting annually as ‘an
overview of regular dialysis treatment in Japan’. According
to the 2011 report, the total number of dialysis patients was
304,592 (2,383 pmp), and the leading cause of ESKD was
diabetes (44.2 %) (Fig. 3) [2]. The mean age has increased
steadily and was 67.8 years in incident and 66.5 years in
prevalent patients (Fig. 4). This result is most likely
explained by the delay in CKD progression and better
survival among the Japanese. The number of patients with
chronic glomerulonephritis has decreased linearly since
Table 1 Risk factors for death in chronic dialysis patients (modified
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Fig. 2 Risk of developing ESKD based on dipstick proteinuria (cited
from ref. [28])
Table 2 Risk factors for the development of ESKD (modified from
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1998, and the mean age at the start of dialysis has increased
from 60.5 years in 1997 to 67.5 years in 2011.
Since 1983, the outcomes of dialysis patients have been
investigated. As shown in the OKIDS data, hypoalbumi-
nemia is a significant predictor of death regardless of the
pre-dialysis blood pressure and use of anti-hypertensive
drugs (Fig. 5) [44]. Survival among Japanese dialysis
patients is better than patients in Europe and the United
States, yet the reasons for this difference remain to be
determined. The demographics and practice patterns differ
in several ways. Patient compliance among Japanese
patients to a dialysis regimen is good. The most common
vascular access is an arteriovenous fistula. A relatively small
body size, with a mean BMI of approximately 21 kg/m2,
might be advantageous for receiving adequate dialysis.
Renal transplantation is performed in approximately
1,000–1,200 patients, and cadaveric donation is stable at
approximately 200 annually.
The early initiation of dialysis has been practiced
worldwide, and the mean initial estimated glomerular
filtration rate (eGFR) is becoming higher than ever before
[45–47]. The eGFR threshold for starting dialysis is not
available. According to the JSDT, the survival was best at
around eGFR 4–6 ml/min/1.73 m2 [48, 49]. The effect of
confounding variables other than age and diabetes is
unknown, and we need more data to determine the eGFR
threshold. Most Japanese nephrologists rely on the research
group criteria supported by the Ministry of Health,
Welfare, and Labor, which use eGFR and the presence of
uremic symptoms. The threshold for manifesting ‘uremic
symptoms’ is variable between patients. Judging the ‘right
timing’ would be determined ideally by the physician,
patient, and family. Continuing conservative management
without dialysis is an alternative option for elderly patients.
The Japanese Society of Nephrology (JSN)
The JSN has published the ‘Clinical Practice Guidebook
for Diagnosis and Treatment of Chronic Kidney Disease’ in
2007, 2009, and 2012 [50]. The ‘‘Evidence-based Practice
Guideline for the treatment of CKD’’ was published in
2009 and will be updated in 2013 [51]. The JSN has been
raising awareness of CKD on World Kidney Day, which is
on the second Thursday in March. Importantly, Japanese
patients generally have a lower eGFR compared to
American patients. Therefore, an eGFR C60 ml/min/
1.73 m2 is considered to be normal for someone who is
otherwise healthy. Albuminuria can only be measured and
reimbursed for patients with early-stage diabetic kidney
disease in Japan. Instead, the JSN advocates using dipstick
proteinuria or measuring the daily amount of proteinuria.
The JSN has been supporting the research project
‘Frontier of Renal Outcome Modifications in Japan’
(FROM-J) [52]. To prevent or halt CKD and ESKD, gen-
eral practitioners and medical staff, such as dieticians and
public health nurses, must be involved. The JSN referral
criteria for nephrologists were published to facilitate
comprehensive care for CKD patients (Table 3) [50].
Additionally, the Asian Forum of CKD Initiatives
(AFCKDI) was started to exchange information on CKD at
the inaugural 50th JSN meeting in Hamamatsu in 2007.
Since 2008, the special health check system (so-called
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Mean age
1997    2007    2011
CGN 60.5    66.4     67.5
DM 62.5    65.4     66.1
NScl 71.4    73.7     74.2
Fig. 3 Causes of primary
kidney disease among
hemodialysis patients in Japan
(cited from ref. [2])
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metabolic syndrome and direct them towards a healthy
lifestyle. The target population is the 40–74 year age
group. The new ‘Kidney Disease: Global Outcomes
Improving Outcomes’ (KDIGO) CKD classification prev-
alence of hypertension was clearly dependent on eGFR and
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Fig. 4 Mean age of chronic








































No antihypertensives AntihypertensiveFig. 5 Annual mortality rate of
dialysis patients based on pre-
hemodialysis blood pressure
and serum albumin (cited from
ref. [44])
Table 3 JSN criteria for referring CKD patients to a nephrologist
(cited from ref. [50])
Proteinuria (C2? by dipstick proteinuria)
Combined proteinuria and hematuria (both 1? and over by
dipstick proteinuria)
Low eGFR (\50 ml/min/1.73 m2): \60 ml/min/1.73 m2 (if age
















Fig. 6 Prevalence of hypertension based on the new KDIGO CKD
classification (cited from ref. [53])
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was dependent on both eGFR and proteinuria. Thus, the
JSN is negotiating for a better screening system for CKD in
Japan. The JSN has launched web-based registries for CKD
and kidney biopsy recipients [54, 55]. Several other
research projects are currently being conducted.
Kidney Disease: Global Outcomes Improving Outcomes
Since the introduction of the concept of CKD, the defini-
tion has been challenged with several criticisms: (1) the
classification was too simple, (2) lack of key outcomes of
CKD, and (3) significance of testing eGFR and albumin-
uria. In this setting, the KDIGO-Controversies Conference
was held from October 4–6, 2009 in London [56]. We
offered the dataset, including serum creatinine and dipstick
proteinuria, for the conference. After the conference, the
CKD classification was slightly modified and expressed as
‘the CKD heat map’. The clinical impacts of eGFR and
albuminuria were investigated for several major outcomes
[57–61].
To further examine the significance of the classification,
the KDIGO CKD prognosis consortium (PC) was orga-
nized. We are privileged that the Okinawa 1983/1993
cohorts were involved in the KDIGO-PC. The phase 2
analyses have already been completed for seven major
topics, such as hypertension, diabetes, gender, ethnicity,
age, CKD epidemiology collaboration, and cystatin C
[62–64]. The significance of a low eGFR and albuminuria
was confirmed for all-cause mortality and cardiovascular
mortality. The relative risks of these markers were similar,
but the absolute risks were different based on age, sex, and
the presence of diabetes or hypertension. Currently, there
will be an additional 13 topics in the Phase 3 step to be
studied soon. The new KDIGO ‘Clinical Practice Guide-
line’ will be published shortly [65].
Summary
CKD is common but treatable if detected early and prop-
erly managed. At an early CKD stage, patients are usually
asymptomatic; therefore, regular health checks using a
urine dipstick and serum creatinine are recommended. The
intervals for follow-up, however, are debatable due to the
cost. In this regard, subjects with hypertension, diabetes,
anemia, and/or metabolic syndrome have the highest risk of
CKD (Fig. 7). Other factors, such as dyslipidemia, hyper-
uricemia, gout, CVD and/or a family history of CKD or
ESKD, also have a high risk for CKD. Such people should
have serum creatinine and albuminuria (proteinuria)
assessed at least annually.
CKD patients are at risk of developing acute kidney
injury due to contrast media, nephrotoxic drugs, surgery,
and dehydration. CKD is a strong risk factor for developing
CVD and death and also plays an important role in infec-
tion and malignancies, particularly in elderly people.
People can live longer with healthy kidneys.
Personal perspective
Japan is a front runner in ‘the new society’ of a world
where the elderly population (C65 years) is the most pre-
valent, reaching 30 % in 2020 [66]. Moreover, the total
population is decreasing. Japan is the leader of medicine
for an aged society and the science of ageing. We need
further studies on the natural history of CKD progression
and GFR trajectory [67]. High-quality observational stud-
ies could promote basic science and stimulate the invention
of new treatments for CKD. The mechanisms of age-rela-
ted GFR decline are entirely unknown, and we have no way
to delay the process. Further research on the role of CKD
along with other medical conditions, such as infection,
mental disorders, CKD-MBD, and malignancies is needed,
especially among the elderly population. CKD campaigns
in public and medical communities should be continued in
order to delay, if not prevent, the development of ESKD.
Many cases of CKD are left unrecognized, but the condi-
tion can be treated even at late stages, so screening is
always beneficial.
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